Modulation of mGluR1 signaling improves Purkinje cell dysfunction associated with spinocerebellar ataxia 14
簡単な紹介:
- 著者: Zsófia Sziber, Shiqi Tang, Paula Torrents-Solé, Aleksandar Kovacevic, Josef P Kapfhammer
- ジャーナル: iScience
- Doi: 10.1016/j.isci.2026.117976
- 発行日: 2026/11/20
Abstract
Spinocerebellar ataxia type 14 (SCA14) is caused by mutations in protein kinase C gamma (PKCγ) that lead to constitutive kinase activity and Purkinje cell dysfunction in the cerebellum. PKCγ acts downstream of metabotropic glutamate receptor 1 (mGluR1) signaling; however, it remains unclear whether alterations in this upstream pathway contribute to the cellular defects induced by mutant PKCγ. Here, we investigated the role of mGluR1 signaling in PKCγ-dependent pathology using organotypic cerebellar slice cultures from a mouse model of SCA14. Modulation of mGluR1 signaling partially improved dendritic abnormalities and dendritic spine phenotypes associated with constitutive PKCγ activation. In addition, inhibition of mGluR1 reduced phosphorylation of PKC substrates and restored the enrichment of scaffold proteins and their synaptic proximity to mGluR1. Together, our results demonstrate that mGluR1 signaling contributes to Purkinje cell abnormalities induced by constitutive PKCγ activity and that modulation of mGluR1 can improve disease-associated cellular phenotypes in SCA14.
PackGeneについて
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
